Royal Bank Of Canada Lowers Evolent Health (NYSE:EVH) Price Target to $3.00

Evolent Health (NYSE:EVH) had its target price dropped by equities research analysts at Royal Bank Of Canada from $5.00 to $3.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “sector perform” rating on the technology company’s stock. Royal Bank Of Canada’s target price suggests a potential downside of 9.91% from the stock’s previous close.

A number of other brokerages also recently issued reports on EVH. Piper Sandler set a $6.00 price objective on Evolent Health in a research report on Tuesday, December 2nd. Canaccord Genuity Group lowered their target price on shares of Evolent Health from $16.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolent Health in a research report on Monday, December 29th. KeyCorp lowered shares of Evolent Health from an “overweight” rating to a “sector weight” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Evolent Health from $13.00 to $7.00 and set an “overweight” rating for the company in a research report on Monday, November 17th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $6.50.

Evolent Health Stock Up 6.1%

EVH stock opened at $3.33 on Wednesday. Evolent Health has a one year low of $2.50 and a one year high of $12.06. The firm has a market cap of $371.63 million, a PE ratio of -0.65 and a beta of 0.27. The firm’s 50 day moving average price is $3.50 and its 200-day moving average price is $5.84. The company has a debt-to-equity ratio of 1.25, a quick ratio of 1.33 and a current ratio of 1.33.

Evolent Health (NYSE:EVH) last posted its earnings results on Tuesday, February 24th. The technology company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. Evolent Health had a positive return on equity of 1.30% and a negative net margin of 28.49%.The company had revenue of $468.72 million during the quarter, compared to analysts’ expectations of $468.48 million. During the same quarter last year, the firm earned ($0.02) earnings per share. The firm’s quarterly revenue was down 27.5% compared to the same quarter last year. On average, equities research analysts anticipate that Evolent Health will post 0.08 EPS for the current year.

Hedge Funds Weigh In On Evolent Health

Several institutional investors have recently modified their holdings of EVH. Brighton Jones LLC purchased a new stake in shares of Evolent Health during the fourth quarter worth $3,927,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Evolent Health by 2.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company’s stock worth $1,217,000 after purchasing an additional 3,572 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Evolent Health by 162.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company’s stock worth $26,861,000 after purchasing an additional 1,754,520 shares during the period. Caxton Associates LLP acquired a new stake in Evolent Health in the 1st quarter valued at about $252,000. Finally, Strs Ohio acquired a new stake in Evolent Health in the 1st quarter valued at about $47,000.

More Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Q4 earnings beat — Evolent posted $0.08 EPS vs. consensus $0.06, turning profitable year-over-year and giving investors a near-term catalyst. Evolent Health (EVH) Q4 Earnings Top Estimates
• Positive Sentiment: Management to participate in investor conferences with live webcasts — increases visibility and gives investors direct access to management’s strategy and outlook. Evolent to Participate in Upcoming Investor Conferences
• Positive Sentiment: Some analysts maintain buy ratings and still show upside — BTIG (new $8 PT) and UBS (new $5 PT) kept buy calls, signaling continued institutional conviction despite lower targets. Evolent Health (NYSE:EVH) Given New $8.00 Price Target at BTIG Research
• Neutral Sentiment: Market commentary and analysis highlight turnaround potential and technical momentum — pieces noting EVH as “cheap, levered, but ready to rebound” and coverage of the intraday move provide narrative context rather than new fundamentals. Evolent Health: Cheap, Levered, But Ready To Rebound
• Neutral Sentiment: Investor note/roundups covering the share move summarize news flow for traders but don’t add new company data. Evolent Health (EVH) Shares Skyrocket, What You Need To Know
• Negative Sentiment: Multiple price-target cuts and a downgrade — several firms lowered PTs (Needham, Citi, RBC, UBS) and KeyCorp downgraded EVH to sector weight, which increases near-term downside risk and reflects investor concerns about top-line declines and leverage. Benzinga coverage of analyst actions
• Negative Sentiment: Revenue decline and margin pressure remain issues — revenue was roughly flat to consensus but down year-over-year, and the company still reports negative net margins, which could limit investor enthusiasm absent clear margin improvement. Evolent Health, Inc. Q4 2025 Earnings Call Transcript

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.